» Articles » PMID: 7002567

Time-course of the Anti-hypertensive Action of Atenolol: Comparison of Response to First Dose and to Maintained Oral Administration

Overview
Specialty Pharmacology
Date 1980 Nov 1
PMID 7002567
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

To show whether repeated administration of atenolol for several days would influence its pharmacokinetic parameters and the extent and duration of the pharmacologic responses, the plasma level of atenolol and changes in heart rate, blood pressure and plasma renin activity were measured in 12 hypertensive patients at various times of day (9 a. m., 12 noon, 3 p. m. and 7 p. m.) after oral administration of the first dose of atenolol 100 mg, again during the 7th and 14th days of continued once-daily administration of the same dose, and finally during the three days following withdrawal of the drug. The peak plasma concentration of atenolol (about 600 ng/ml) was found 3 h after administration of the first dose, and measurable amounts (50-70 ng/ml) were found after 24 h. None of the pharmacokinetic characteristics were changed by administration of a single daily dose for two weeks. After withdrawal of the drug, detectable amounts of atenolol were found in plasma for at least 48 h. The first dose of atenolol caused prompt (3 h) and prolonged (up to 24 h) lowering of supine and standing systolic and diastolic blood pressures, slowing of supine and standing heart rate, reduction of the blood pressure and heart rate responses to dynamic exercise, and a decrease in plasma renin activity. The extent and time-course of all these responses were not influenced by repeated once-daily administration of the 100 mg dose for two weeks. Most of the effects continued during the withdrawal days, the lowering of blood pressure being somewhat more prolonged than the slowing of heart rate. It is concluded that a once-daily dose of atenolol 100 mg decreases blood pressure and heart rate throughout the following 24 h, without excessive daily fluctuation in its effects, and without signs of tolerance or accumulation.

Citing Articles

Interoceptive Signals Bias Decision Making in Rhesus Macaques.

Cardenas M, Le R, Champ T, ONeill D, Fuglevand A, Gothard K bioRxiv. 2024; .

PMID: 39026888 PMC: 11257560. DOI: 10.1101/2024.07.08.602563.


A Human Stem Cell-Derived Brain-Liver Chip for Assessing Blood-Brain-Barrier Permeation of Pharmaceutical Drugs.

Koenig L, Ramme A, Faust D, Mayer M, Flotke T, Gerhartl A Cells. 2022; 11(20).

PMID: 36291161 PMC: 9600760. DOI: 10.3390/cells11203295.


Medications for Hypertension Change the Secretome Profile from Marrow Stromal Cells and Peripheral Blood Monocytes.

Satani N, Giridhar K, Cai C, Wewior N, Norris D, Aronowski J Stem Cells Int. 2020; 2020:8894168.

PMID: 32802081 PMC: 7416264. DOI: 10.1155/2020/8894168.


Synthesis and Characterisation of a Monolithic Imprinted Column Using a Methacrylic Acid Monomer with Porogen Propanol for Atenolol Analysis.

Hasanah A, Maelaningsih F, Apriliandi F, Sabarudin A J Anal Methods Chem. 2020; 2020:3027618.

PMID: 32190401 PMC: 7064834. DOI: 10.1155/2020/3027618.


Biological sample preparation by using restricted-access nanoparticles prepared from bovine serum albumin: application to liquid chromatographic determination of β-blockers.

Rosa M, de Faria H, Carvalho D, Figueiredo E Mikrochim Acta. 2019; 186(9):647.

PMID: 31456048 DOI: 10.1007/s00604-019-3774-1.


References
1.
Haber E, Koerner T, PAGE L, KLIMAN B, Purnode A . Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969; 29(10):1349-55. DOI: 10.1210/jcem-29-10-1349. View

2.
Marshall A, Barritt D, Harry J . Dose response and frequency of administration of atenolol in essential hypertension--once daily treatment with beta-blockade. Postgrad Med J. 1977; 53 Suppl 3:168-72. View

3.
Cruickshank J . Once-daily dosing with Atenolol in patients with mild or moderate hypertension. Br Med J. 1976; 1(6016):990-1. PMC: 1639643. DOI: 10.1136/bmj.1.6016.990. View

4.
Castleden C, Dathan J, George C . A comparison of once and twice daily atenolol in hypertension. Postgrad Med J. 1977; 53(625):679-82. PMC: 2496839. DOI: 10.1136/pgmj.53.625.679. View

5.
SCALES B, Copsey P . The gas chromatographic determination of atenolol in biological samples. J Pharm Pharmacol. 1975; 27(6):430-3. DOI: 10.1111/j.2042-7158.1975.tb09473.x. View